Soleno Therapeutics to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease
September 19 2018 - 8:00AM
Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage
biopharmaceutical company developing novel therapeutics for the
treatment of rare diseases, today announced that Anish Bhatnagar,
M.D., Chief Executive Officer, will conduct one-on-one investor
meetings at the Oppenheimer Fall Summit Focused on Specialty Pharma
and Rare Disease, being held September 26-27, 2018, in New York,
NY.
About Soleno Therapeutics, Inc.Soleno is
focused on the development and commercialization of novel
therapeutics for the treatment of rare diseases. The company’s lead
candidate, DCCR, a once-daily oral tablet for the treatment of PWS,
is currently being evaluated in a Phase III clinical development
program.
For more information, please
visit www.soleno.life.
CONTACT:Brian RitchieLifeSci Advisors,
LLC212-915-2578
Soleno Therapeutics (NASDAQ:SLNO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Soleno Therapeutics (NASDAQ:SLNO)
Historical Stock Chart
From Sep 2023 to Sep 2024